In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-Nerve Growth Factor Developers Face Go/No-Go Recommendation From Advisory Panel

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA sets March 12 as date for the Arthritis Advisory Committee to weigh in on whether safety issues are a barrier to development of anti-NGF compounds as analgesics. Developers’ trials are on hold while FDA considers the potential for adverse effects seen in osteoarthritis patients taking the monoclonal antibodies for pain.

You may also be interested in...



Anti-NGFs Advisory Committee Postponed As FDA Reviews New Information

The agency is assessing safety signals for the biologics, which are being developed for chronic pain.

Regeneron, J&J, AstraZeneca Pull Plug On NGF Inhibitors In Development For Pain Indications

The three companies' decisions were spurred by concerns about potential for the bone disorder avascular necrosis.

No Relief For Pfizer As It Shuts Down Additional Tanezumab Trials

Safety concerns require Pfizer to scupper two additional studies of its Phase III tanezumab, casting doubt on an entire class of new pain drugs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel